$IRLA News
Last published 4h ago
- 4h agoIRLAIRulya Therapeutics Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 12h agoIRLAIRulya Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial ResultsGlobeNewswireName changed from Quince Therapeutics, Inc. to IRulya Therapeutics Inc.; common stock began trading on the Nasdaq Capital Market under the ticker “IRLA” on October 12, 2026
- 4d agoIRLAIRulya Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireNEW HAVEN, Conn., Nov. 09, 2026 (GLOBE NEWSWIRE) -- IRulya Therapeutics Inc. (Nasdaq: IRLA), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, today announced that on November 9, 2026, IRulya granted restricted stock units representing a total of 83,513 shares of common stock to three (3) new employees.
- 4d agoIRLAIRulya Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireNEW HAVEN, Conn., Nov. 09, 2026 (GLOBE NEWSWIRE) -- IRulya Therapeutics Inc. (NASDAQ:IRLA), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious
- 4w agoIRLAIRulya Therapeutics to Participate in the Craig-Hallum Biotech Catalyst ConferenceGlobeNewswireNEW HAVEN, Conn., Oct. 15, 2026 (GLOBE NEWSWIRE) -- IRulya Therapeutics Inc. (NASDAQ:IRLA), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapeutics for serious